With euro area inflation and growth data pointing to improving demand and cooling price pressures, reliable income has fresh appeal. Cash yields no longer look like a one way bet, and investors are paying closer attention to dividends that look sustainable. This is where Dividend Powerhouses with 3%+ yields and solid coverage stand out. This article highlights three of the strongest candidates from that screener.
The three stocks covered next are only a small sample of what this idea turns up, with the full screen surfacing more than 450 additional companies that also offer compelling dividend stories that are not covered here. To see the wider opportunity set, head straight into the Dividend Powerhouses (3%+ Yield) screener to identify, filter and analyze the dividend stocks that best fit your own income goals.
Canon (TSE:7751)
Canon is a global electronics group that designs and sells printers, cameras, medical imaging systems and industrial equipment. It is still heavily driven by its Printing segment, which generated about ¥2.5t revenue, followed by Imaging at roughly ¥1.1t, Medical at about ¥579b and Industrial at about ¥347b, with smaller contributions and internal eliminations rounding out the total. The company is a large cap, with a market value of roughly ¥3.8t, which puts it firmly in the global blue chip bracket for income focused investors.
Income investors may want to pay attention to Canon because it combines a globally diversified business in printing, imaging and medical equipment with solid profitability and recent buybacks that reduce the share count. Earnings and margins have been moving in the right direction, with net profit margin at 7.4% and recent half year results showing higher sales and earnings, which supports the case for dividend capacity. At the same time, an uneven dividend history, slower revenue growth expectations and governance questions around board independence and funding risk mean the stock is not without issues. For patient investors willing to weigh those trade offs, Canon could be more interesting than its low P/E ratio alone suggests.
Canon’s earnings strength and buybacks could be masking a deeper shift in its income story. Get the full context in the 4 key rewards and 1 important warning sign and see the trade off that long-term holders cannot ignore.
Build your own dividend powerhouse shortlist
Canon and the two other stocks in this article are just a few examples of what a focused screen can surface. Use our flexible Screener to mix filters such as valuation, balance sheet strength, risks and dividend profile to match your plan, or tap into our curated Investing Ideas for ready made starting points.
Daiichi Sankyo Company (TSE:4568)
Daiichi Sankyo Company is a global pharmaceutical group focused on cancer and specialty medicines, with a portfolio that spans oncology, cardiovascular, metabolic, vaccine and neurology treatments. Its revenue of about ¥2,223.2b comes almost entirely from its Pharmaceutical Operation segment, which includes key cancer drugs like Enhertu and Datroway, iron deficiency treatments, anticoagulants and vaccines. The company has a market value of roughly ¥4.7t, putting it among the larger listed drug makers in Japan.
Daiichi Sankyo is positioned in the center of growing oncology demand, with recent EU and US approvals for Enhertu and Datroway and raised revenue guidance indicating momentum in its core cancer franchise. Analysts currently project earnings and revenue growth, and the stock trades at a 3.87% dividend yield and around 49.5% below one estimate of fair value. However, this comes with clear trade offs. Cash flows currently leave the dividend less than comfortably covered, margins have eased from 15.4% to 10.9%, and the company leans heavily on a small group of blockbuster drugs and rising R&D spend. For income-focused investors who can tolerate these risks, Daiichi Sankyo offers a combination of growth exposure and yield that may warrant closer examination.
Daiichi Sankyo’s oncology engine and 3.87% yield sit on a tightrope of blockbuster reliance and softer margins. Before you lean into that mix of growth and income, read the 2 key rewards and 1 important warning sign
Japan Tobacco (TSE:2914)
Japan Tobacco is a global tobacco and food company that sells cigarettes, cigars, heated and infused tobacco products, e-vapor and oral products, alongside frozen foods and seasonings. It is primarily a tobacco business, with the Tobacco segment generating about ¥3.6t revenue compared with roughly ¥162b from Processed Food and a small contribution from Others. The company is a major player on the Tokyo market, with a market value of around ¥12.1t.
Income focused investors may want to look at Japan Tobacco because it pairs a 3.99% dividend yield with strong recent earnings momentum and guidance that points to solid profitability in 2026. The core story is a shift toward reduced risk and premium products, backed by a planned ¥650b investment in next generation offerings and recent deals like the EUR 176m fine cut acquisition that deepen the portfolio. At the same time, heavy reliance on a shrinking Japanese combustibles market, an RRP segment that is still loss making and funding fully backed by external borrowing keep risk firmly on the table. The real question is whether that mix of premium pricing power, global expansion and governance change offsets the structural headwinds facing tobacco and supports a durable dividend story over the longer term.
Japan Tobacco’s push into reduced risk and premium products could be reshaping the whole income story, while headline yield grabs the attention. To see how that balance of progress and pressure really stacks up, read the 3 key rewards and 1 important warning sign
Seeking Fresh Alternatives Beyond Dividends
Some of the most interesting ideas move first and get noticed later. Before the next breakout gathers momentum and flies out of reach, scan these fresh lists and act now.
- Spot companies quietly building strength before momentum headlines catch up. Work through the curated list of solid balance sheet and fundamentals (39 results) while that information edge still matters.
- Track where real profits meet AI hype by checking the hand picked 67 profitable AI stocks that aren't just burning cash before valuations run away from the underlying cash generation.
- Follow the early moves in electricity demand shifts and grid upgrades by reviewing the focused 36 power grid technology and infrastructure stocks while many of these stocks remain under the radar for now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com